There is a lot of uncertainty as to what the UK healthcare industry will look like post-Brexit, with almost half of respondents in a recent global survey of industry professionals indicating that the regulatory implications of the country leaving the European Economic Area (EEA) would have the biggest impact.
Negotiations are ongoing to determine the UK鈥檚 post-Brexit relationship with the EU.
GlobalData鈥檚 new report, 鈥樷�� provides an assessment of how the pharmaceutical industry expects Brexit to affect the healthcare sector. Based on the results, the report recommends that healthcare companies invest resources into managing the potential regulatory implications for the industry following the UK鈥檚 departure.
What effects will Brexit have in the healthcare sector?
When asked if the UK would be an attractive destination for research and manufacturing post-Brexit, the split was divided almost in half for US and UK respondents, but the majority of EU respondents said they did not see the UK as an appealing location.
Alexandra Annis, senior pharma analyst at GlobalData, said: 鈥淪ubstantial uncertainty exists around the UK鈥檚 position in the healthcare industry after Brexit. Will the UK remain a member of the EEA? Will the UK have access to EU funding? These questions leave the UK a high-risk market for healthcare companies to invest in research and manufacturing.鈥�
Highlights of the report include:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData- The key factors expected to impact the post-Brexit UK healthcare industry
- The impact post-Brexit has on research and manufacturing
- Level of Impact on Corporate Strategy
- Impact on relocation 鈥� Pharma companies may opt to relocate staff from the UK to the EU due to loss of 鈥榩assporting鈥� rights
GlobalData鈥檚 latest report will help to develop and design your corporate strategies post-Brexit through expert analysis, as well as develop business strategies. Gain a competitive advantage by identifying emerging industry trends, and stay up-to-date with the industry鈥檚 changing sentiment towards Brexit with GlobalData鈥檚 quarterly surveys.
If you would like any more information on this report, please visit the GlobalData .
